ELOVL7

ELOVL7 is a fatty acid elongase that extends saturated and unsaturated very-long-chain fatty acids, functioning in phospholipid and cholesterol ester remodeling with downstream consequences for steroidogenesis, inflammation, and cell death. ELOVL7 preferentially elongates saturated VLCFAs (≥C20:0) in prostate cancer cells, where its knockdown depletes SVLCFA-containing lipid species and reduces de novo androgen synthesis, and also elongates unsaturated fatty acids (C16:1, C18 series) in mammary epithelial cells (PMID:19826053, PMID:31242694). Transcriptionally, ELOVL7 is regulated by SREBP1 downstream of androgen signaling and the fumarate hydratase–malate metabolic axis, and by NF-κB in M1-polarized macrophages, where it promotes IL-6 and IL-12/IL-23 p40 cytokine secretion (PMID:19826053, PMID:40940503, PMID:37251958). In injured podocytes, ELOVL7 upregulation drives accumulation of phospholipids bearing long-chain polyunsaturated fatty acid tails, increasing lipid peroxidation and sensitizing cells to ferroptosis, as confirmed by podocyte-specific knockout in mice (PMID:41285716).

1. 2009 High

   Establishing ELOVL7 as an SVLCFA elongase linked to androgen-dependent prostate cancer metabolism answered the question of what enzymatic activity the gene encodes and placed it in a disease-relevant lipid pathway.

   Evidence In vitro fatty acid elongation assay, siRNA knockdown with lipid profiling and de novo androgen synthesis measurement in prostate cancer cells

   PMID:19826053

   Open questions at the time

   • Structural basis for substrate selectivity (saturated vs. unsaturated VLCFAs) not determined
   • Whether ELOVL7-dependent cholesterol ester remodeling is required for androgen synthesis in vivo remains untested
   • Transcriptional regulation by SREBP1 demonstrated in one cell system only
2. 2019 Medium

   Demonstrating that ELOVL7 also elongates unsaturated fatty acids (C16:1, C18 series) in mammary epithelial cells broadened the substrate profile beyond saturated VLCFAs and indicated tissue-dependent substrate preference.

   Evidence Overexpression and knockdown in primary goat mammary epithelial cells with fatty acid composition analysis and elongation index calculation

   PMID:31242694

   Open questions at the time

   • Species-specific substrate selectivity not resolved against human orthologue
   • No purified enzyme kinetics to quantify relative affinities for saturated vs. unsaturated substrates
   • Single lab, awaits independent replication
3. 2023 Medium

   Identifying NF-κB as the transcriptional driver of ELOVL7 in M1-like macrophages, and showing that ELOVL7 knockdown suppresses IL-6 and IL-12/IL-23 p40 production, established a role for ELOVL7 in innate immune inflammatory output.

   Evidence NF-κB and STAT1 inhibitor epistasis, siRNA knockdown, and cytokine ELISA in THP-1-derived macrophages

   PMID:37251958

   Open questions at the time

   • Which ELOVL7-generated lipid species mediate cytokine regulation is unknown
   • Not tested in primary human macrophages or in vivo inflammatory models
   • Single lab without independent confirmation
4. 2025 Medium

   Positioning ELOVL7 downstream of the fumarate hydratase–malate–SREBP axis in cardiomyocytes, where its overexpression reverses FH-mediated cardioprotection, revealed a metabolic node linking TCA cycle intermediates to pathological cardiac lipid remodeling.

   Evidence AAV9-FH overexpression in TAC mice, RNA-seq, metabolomics, Elovl7 overexpression rescue, SREBP knockdown

   PMID:40940503

   Open questions at the time

   • Specific VLCFA species mediating cardiac hypertrophy not identified
   • Single lab, no independent replication yet
   • Whether cardiac ELOVL7 regulation by SREBP shares the same promoter elements as in prostate cancer is unresolved
5. 2025 High

   Showing that podocyte ELOVL7 upregulation drives LC-PUFA-containing phospholipid accumulation, lipid peroxidation, and ferroptosis — validated by podocyte-specific knockout — established ELOVL7 as a determinant of ferroptosis susceptibility through membrane lipid composition.

   Evidence Single-nucleus RNA-seq, targeted lipidomics, podocyte-specific Elovl7 knockout mice, siRNA knockdown, ferroptosis assays

   PMID:41285716

   Open questions at the time

   • Direct identification of the peroxidation-prone phospholipid species generated by ELOVL7 is incomplete
   • Whether ELOVL7-driven ferroptosis sensitization operates in cell types beyond podocytes is untested
   • Interaction with GPX4 or other ferroptosis defense systems not characterized

• No crystal or cryo-EM structure of ELOVL7 exists, the molecular basis for its dual saturated/unsaturated substrate selectivity is unresolved, and in vivo contributions of ELOVL7 to systemic lipid homeostasis in full-body knockout models have not been reported.
• No structural model of ELOVL7
• No full-body knockout phenotyping reported
• Relative contributions of ELOVL7 vs. other ELOVL family members to overlapping substrates not dissected in vivo